Reforgene Medicine, a prominent gene editing therapy company headquartered in Guangzhou, has reportedly secured hundreds of millions of renminbi in a new financing round. This funding round was led by Guangzhou Industry Investment, with additional contributions from Guangzhou Financial Holdings, Technology Financial Holdings, and returning investor IFSC. The capital raised will be instrumental in strengthening the company’s gene therapy clinical studies, following its pipeline expansion and core technology innovation.
Enhancing Clinical Studies and Technology Innovation
Founded in 2019, Reforgene Medicine has made significant strides in the field of gene therapy. The company’s RM-001, a therapy for β-thalassemia, has initiated the first clinical study worldwide based on a new target gene therapy approach. Additionally, its gene editing drug RM-004 has successfully treated the first patient with α-thalassemia, marking a milestone in the treatment of this genetic blood disorder.
Global Clinical Approvals and Pipeline Development
Reforgene Medicine’s RM-101, a potential first-in-class drug for the retinal disease Usher syndrome, has received clinical approvals in both China and the US this year. This achievement underscores the company’s commitment to developing innovative therapies for rare and challenging diseases. Furthermore, the company is actively developing in vivo gene editing therapies targeting the central nervous system and liver, demonstrating its broad reach in the gene editing space.Fineline Info & Tech
